Last updated: September 4, 2026
Pafolacianine sodium, marketed as Cytalux by On Target Laboratories, is a folate receptor-targeted fluorescent imaging agent used during cancer surgery. FDA approval covers intraoperative identification of ovarian cancer lesions and pulmonary lesions in adults with suspected or known cancer. Its commercial opportunity depends on operating-room adoption, reimbursement, surgeon training, and expansion beyond the initial ovarian-cancer market.
On Target Laboratories is privately held, so product revenue, unit volume, gross margin, cash burn, and profitability are not publicly reported. The commercial trajectory is therefore assessed through FDA milestones, label expansion, financing activity, market access, competitive technology, and procedure adoption rather than audited product-level financials.
What is pafolacianine sodium and how does Cytalux work?
Pafolacianine sodium is an intravenous fluorescent imaging agent that binds folate receptor alpha, or FRα, on certain malignant cells. When illuminated with near-infrared light during surgery, the agent helps surgeons identify lesions that may not be visible or palpable under standard visualization.
Cytalux is an adjunct to surgery. It does not replace histopathology, conventional imaging, or the surgeon’s clinical judgment. The commercial value proposition is improved lesion visualization, potentially supporting more complete resection and reducing residual disease.
FDA-approved indications
| Milestone |
Date |
Commercial significance |
| FDA approval for ovarian cancer surgery |
November 29, 2021 |
Established Cytalux as the first approved FRα-targeted intraoperative imaging agent in the United States |
| FDA supplemental approval for pulmonary lesions |
December 2023 |
Expanded the addressable market from gynecologic oncology into thoracic surgery |
| Current marketed indication |
2024 onward |
Adjunctive visualization of ovarian and pulmonary malignant lesions in adults |
The ovarian indication applies to adult patients with ovarian cancer undergoing surgery. The pulmonary indication covers adults with known or suspected cancer who are undergoing surgery for pulmonary lesions. The FDA label specifies dosing, infusion timing, warnings, adverse reactions, and limitations of use.[1,2]
How large is the pafolacianine sodium market?
The market is a specialized segment of intraoperative molecular imaging rather than a conventional chronic pharmaceutical market. Revenue depends on the number of eligible surgeries in which a hospital adopts the technology and administers the product.
Primary market drivers
The main demand drivers are:
- Rising use of minimally invasive surgery and video-assisted thoracic surgery.
- Increased use of segmentectomy and sublobar resection for early-stage lung cancer.
- Need to identify small, nonpalpable, multifocal, or occult lesions.
- Expansion of fluorescence-enabled surgical platforms.
- Greater interest in molecular imaging that adds information beyond anatomy.
- Potential reduction in incomplete resection or unrecognized lesions.
The ovarian market provides a concentrated initial customer base in gynecologic oncology. The pulmonary indication substantially enlarges the procedural pool because lung cancer surgery occurs at a higher annual volume than ovarian cancer surgery.
Market constraints
Adoption remains sensitive to operating-room economics. Hospitals must have access to compatible near-infrared visualization equipment, establish pharmacy and scheduling procedures, train surgeons and operating-room personnel, and obtain reimbursement or absorb the cost within bundled surgical payments.
Cytalux is also used in a procedure-specific setting. A hospital does not generate recurring revenue from daily prescriptions or chronic therapy. Utilization rises when a surgeon incorporates the agent into a defined surgical workflow and falls when the product is viewed as discretionary.
What is the financial trajectory of Cytalux and On Target Laboratories?
On Target Laboratories is a private company and does not publish the financial disclosures required of a public pharmaceutical issuer. Publicly available information does not establish audited Cytalux revenue, quarterly sales, unit shipments, gross profit, operating loss, or cash-flow performance.
The financial trajectory can be divided into four stages.
Development and regulatory financing
On Target Laboratories financed clinical development and regulatory work through private capital, including investment associated with Deerfield Management and other institutional backers. The company’s funding model reflects the cost structure of an imaging product that requires clinical trials, regulatory submissions, manufacturing scale-up, commercial infrastructure, and hospital implementation.
Initial launch in ovarian cancer
The 2021 approval created a commercial launch platform but did not immediately produce a broad oncology market. Ovarian surgery is concentrated among specialized centers, and adoption requires the surgeon to change an established procedure.
Early commercial costs likely included:
- Medical-affairs and surgical training teams.
- Hospital formulary and value-analysis submissions.
- Distribution and specialty-pharmacy infrastructure.
- Operating-room equipment compatibility work.
- Payer coding and reimbursement support.
- Postmarketing evidence generation.
Because product-level sales are private, the financial effect of the ovarian launch cannot be quantified from public filings.
Expansion into pulmonary surgery
The December 2023 lung indication changed the market profile. Thoracic surgery expands the number of potential procedures and creates opportunities for use in hospitals that may not have large gynecologic-oncology programs.
The lung indication also creates a broader clinical use case. Pulmonary nodules can be small, deep, nonpalpable, or difficult to localize during minimally invasive surgery. A molecular fluorescence signal can therefore complement preoperative imaging and localization methods.
Medium-term commercial phase
The near-term financial trajectory depends on utilization per account rather than regulatory approval alone. A positive trajectory would require:
- Conversion of initial hospitals from evaluation to routine use.
- Expansion from academic centers to community hospitals.
- Reimbursement that covers product and procedure costs.
- Repeat use across multiple surgeons in each institution.
- Evidence showing operational or clinical value in lung and ovarian surgery.
- Expansion into additional FRα-positive or folate-receptor-targeted surgical settings.
Absent public revenue reporting, the most important commercial indicators are hospital account growth, recurring procedure volume, geographic coverage, reimbursement decisions, and surgeon adoption.
What is the price and reimbursement outlook for pafolacianine sodium?
Cytalux is a single-use, procedure-linked drug. Its economic value is assessed against the cost of surgery, operating-room time, imaging equipment, and downstream consequences of missed or incompletely resected lesions.
Public pricing information has not produced a consistent, audited net-price benchmark. Actual economics can vary by purchasing agreement, distributor terms, payer mix, hospital contract, and whether the product is separately reimbursed or included in a facility payment.
Reimbursement risks
The principal reimbursement risks are:
- Product cost not being separately recognized by the payer.
- Hospital reluctance to purchase an agent without predictable case volume.
- Variable use across Medicare, commercial, and Medicaid populations.
- Lack of demonstrated savings from reduced reoperation or improved staging.
- Delays in coding, coverage, or payment-policy adoption.
For a specialty imaging agent, reimbursement is often more important than the nominal list price. A high per-vial price can be commercially acceptable if the product improves procedure economics. The same price can restrict adoption if hospitals must fund it from a fixed surgical budget.
What patents and exclusivity protect Cytalux?
Cytalux has protection from a combination of regulatory exclusivity, patents covering pafolacianine-related technology, and proprietary manufacturing and clinical know-how. The practical strength of the estate depends on the scope and remaining life of issued claims, not on the number of patent publications.
Regulatory exclusivity timeline
| Protection |
Relevant date |
Expected effect |
| First U.S. approval |
November 29, 2021 |
Starts the U.S. regulatory exclusivity framework |
| Five-year new chemical entity period, if applicable |
November 2026 |
Blocks submission of an ANDA relying on the reference product during the applicable period, subject to statutory exceptions |
| Orphan-drug exclusivity for the approved orphan indication, if applicable |
Potentially through November 2028 |
Can block approval of the same drug for the same orphan indication |
| Lung supplemental approval |
December 2023 |
May support separate three-year exclusivity for qualifying new clinical investigations, but does not reset NCE exclusivity |
The exact protection available to a generic or competing applicant depends on the FDA’s current exclusivity record and the approved indication. Orphan exclusivity is indication-specific. It does not necessarily block all uses of a competing product.
Orange Book status
Cytalux is approved under NDA 214907. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the controlling source for listed patents and FDA-recognized exclusivity associated with the NDA.[3]
The commercial risk analysis should distinguish three issues:
- Whether a patent is listed for the NDA.
- Whether the listed patent claims cover the proposed generic product or use.
- Whether the patent remains enforceable through the relevant launch date.
A listed patent can trigger a Paragraph IV certification and litigation without guaranteeing that the patent will survive invalidity or non-infringement challenges.
When could generic entry occur?
The earliest generic-entry pathway depends on the interaction of FDA exclusivity, Orange Book listings, patent expiration, and litigation.
Paragraph IV challenges
A generic applicant could challenge a listed patent through a Paragraph IV certification. The reference-product sponsor would generally have 45 days to file an infringement action after receiving notice. A timely suit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court rulings.[4]
For Cytalux, the most credible challenge would likely focus on:
- Composition or conjugate claims.
- Formulation claims.
- Dosing or administration claims.
- Intraoperative imaging methods.
- Claims directed to tumor visualization using folate-receptor binding.
A product-specific ANDA pathway may face technical barriers because pafolacianine is a complex fluorescent conjugate rather than a simple small-molecule tablet. Demonstrating pharmaceutical equivalence, analytical comparability, impurities, fluorescence characteristics, and clinical performance may be more difficult than for a conventional oral generic.
Generic launch scenarios
| Scenario |
Timing logic |
Commercial impact |
| Early settlement launch |
Before full patent expiry, subject to settlement terms |
Limited or royalty-bearing entry may preserve substantial branded share |
| Successful Paragraph IV challenge |
After litigation or invalidity ruling |
Potentially rapid price erosion and hospital substitution |
| At-risk launch |
Generic launches before final patent resolution |
High damages and injunction exposure if the sponsor prevails |
| Patent-term entry |
After enforceable patent and regulatory exclusivity expiry |
Broadest generic competition and strongest price pressure |
| No near-term ANDA |
Complex-product or limited-market economics deter challenge |
Cytalux retains practical protection despite formal expiry risk |
How strong is the pafolacianine sodium patent estate?
The estate is stronger when it combines composition claims with formulation, manufacturing, and method-of-use claims. Composition claims generally provide the broadest barrier because they can cover the active product itself. Method claims can remain commercially useful but are easier to design around if a competitor changes the indication, imaging protocol, patient population, or surgical use.
Technical barriers beyond patent claims
Cytalux’s competitive protection may include:
- Proprietary conjugation chemistry.
- Control of fluorescent impurities and batch consistency.
- Manufacturing know-how.
- Reference standards and analytical methods.
- Clinical evidence supporting use in defined surgical procedures.
- Surgeon familiarity and hospital workflow integration.
- FDA experience with the product’s manufacturing process.
These barriers do not prevent competition but can delay development and raise the cost of a competing product.
Which companies challenge pafolacianine sodium?
No publicly established biosimilar market exists for pafolacianine sodium. The product is not a biologic subject to the conventional biosimilar pathway under the Biologics Price Competition and Innovation Act.
Competition comes from three groups:
Conventional surgical visualization
Indocyanine green is widely used for fluorescence imaging, including perfusion assessment and selected lesion-localization applications. Its lower cost and broad availability are commercial advantages, although it does not provide the same FRα-targeted mechanism.
Alternative molecular imaging agents
Other companies are developing fluorescent or radiolabeled agents targeting folate receptors, fibroblast activation protein, prostate-specific membrane antigen, and other tumor-associated markers. These products may compete in specific tumor types rather than across all Cytalux indications.
Non-drug localization methods
Surgeons may use preoperative CT guidance, bronchoscopic marking, electromagnetic navigation, radioisotope localization, microcoil placement, and intraoperative ultrasound. These are substitutes for some pulmonary lesion-localization use cases.
Cytalux competes on clinical information, workflow simplicity, lesion detection, and economic value. It does not compete solely on drug price.
What litigation and settlement risks affect Cytalux?
Publicly available information does not establish a major, market-defining Paragraph IV litigation campaign against Cytalux. The absence of a disclosed challenge does not eliminate future risk. The relevant litigation triggers would be an ANDA notice, an Orange Book-listed patent, a patent-infringement complaint, or a settlement filed under applicable FDA requirements.
Potential disputes could involve:
- Patent validity under obviousness, written description, or enablement standards.
- Claim construction around folate-receptor targeting.
- Infringement by a different fluorescent linker or salt form.
- Method-of-use claims for ovarian or pulmonary surgery.
- Regulatory exclusivity and indication-specific approval rights.
How does pafolacianine compare with competing imaging approaches?
| Attribute |
Pafolacianine sodium |
Indocyanine green |
Preoperative localization |
| Targeting mechanism |
Folate receptor alpha |
Nonspecific fluorescence and vascular distribution |
Anatomical or image-guided |
| Main use case |
Ovarian and pulmonary lesion identification |
Perfusion and selected visualization uses |
Localization before surgery |
| Drug complexity |
Targeted fluorescent conjugate |
Established small-molecule dye |
Procedure-dependent |
| Equipment |
Near-infrared imaging platform |
Near-infrared imaging platform |
CT, bronchoscopy, navigation, or other systems |
| Commercial strength |
Molecular specificity and differentiated clinical positioning |
Low cost and broad familiarity |
Established workflow in selected centers |
| Main weakness |
Cost, training, reimbursement, and limited indications |
Less tumor-specific information |
Added procedural complexity |
What revenue exposure does pafolacianine create?
The economic exposure is concentrated in On Target Laboratories because the company owns the Cytalux commercial franchise. For hospitals, exposure is primarily procedural and budgetary. For investors or licensing counterparties, the key risk is that regulatory expansion may not translate into recurring use.
The lung indication improves the revenue opportunity but also increases competitive pressure. Thoracic surgeons already have several localization tools, and hospitals may prefer established techniques unless Cytalux produces measurable improvements in lesion detection, conversion rates, resection margins, operating-room time, or reoperation rates.
A commercial inflection point would require evidence of repeat use. One-time evaluation cases do not establish durable revenue. The stronger indicators are monthly cases per institution, use across multiple surgeons, and adoption in community settings.
What is the geographic coverage of Cytalux?
The principal commercial and regulatory market is the United States, where Cytalux has FDA approval. The product’s near-term value is highest in hospitals with:
- Gynecologic-oncology and thoracic-oncology surgery programs.
- Near-infrared imaging capability.
- Access to specialized pharmacy and operating-room support.
- Payers that recognize the procedure’s clinical and economic value.
- Sufficient surgical volume to justify implementation.
International expansion would require country-specific regulatory approvals, reimbursement submissions, local manufacturing and distribution arrangements, and clinical adoption programs. Foreign patent and exclusivity positions may differ materially from the U.S. position.
Key Takeaways
- Pafolacianine sodium is a targeted intraoperative fluorescent imaging agent marketed as Cytalux.
- FDA approvals cover ovarian-cancer surgery and pulmonary-lesion identification.
- The 2023 pulmonary indication expanded the addressable market beyond gynecologic oncology.
- On Target Laboratories is private, so audited product revenue and profitability are not publicly available.
- Commercial adoption depends on hospital workflow, near-infrared equipment, reimbursement, and repeat surgical use.
- Cytalux has no conventional biosimilar pathway because it is not a biologic.
- Generic risk is shaped by complex-product development, regulatory exclusivity, Orange Book listings, and patent scope.
- The main substitutes are indocyanine green, preoperative localization, bronchoscopic marking, electromagnetic navigation, and other molecular imaging agents.
- The most important financial indicators are recurring case volume, account expansion, reimbursement, manufacturing scale, and evidence of improved surgical outcomes.
FAQs
Is pafolacianine sodium a chemotherapy drug?
No. Pafolacianine sodium is an intraoperative diagnostic imaging agent used to help visualize malignant lesions during surgery. It is not a cytotoxic or targeted cancer treatment.
Does Cytalux require a special imaging device?
Yes. Cytalux is used with compatible near-infrared fluorescence imaging equipment. Device availability is a practical prerequisite for hospital adoption.
Can Cytalux be used for cancers other than ovarian and lung cancer?
FDA-approved use is limited to the indications and patient populations in the approved labeling. Off-label use may occur clinically, but it does not carry the same regulatory or reimbursement position.
Is Cytalux eligible for a biosimilar competitor?
No conventional biosimilar pathway applies because pafolacianine sodium is not an FDA-regulated biologic. A competing product would likely require a drug-specific regulatory strategy, potentially involving an ANDA or 505(b)(2) application depending on the product and claims.
What would most improve Cytalux’s commercial value?
The strongest commercial catalysts would be repeat hospital use, broad reimbursement, adoption in community hospitals, evidence of improved lesion detection or resection outcomes, and additional FDA-approved surgical indications.
References
- U.S. Food and Drug Administration. (2021). Cytalux (pafolacianine) injection: Approval letter and prescribing information.
- U.S. Food and Drug Administration. (2023). Cytalux (pafolacianine) injection: Supplemental approval for pulmonary lesion identification.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). Abbreviated new drug application regulations and Paragraph IV certification procedures.
